Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMERA trial in newly diagnosed DMARD-naive rheumatoid arthritis
NL-OMON49359Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of methotrexate, hydroxychloroquine, filgotinib and adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Erasmus MC. Primary endpoints: Proportion of patients using a biologic or targeted synthetic DMARD after 10 months, Disease Activity Score over time and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON49359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49359.